A Double Blind, Double Dummy, Randomized, Placebo-controlled, 5 Period Cross-over Study To Examine The Effect Of Pf-06273340 On Evoked Pain Endpoints In Healthy Volunteers Using Pregabalin And Ibuprofen As Positive Controls

Trial Profile

A Double Blind, Double Dummy, Randomized, Placebo-controlled, 5 Period Cross-over Study To Examine The Effect Of Pf-06273340 On Evoked Pain Endpoints In Healthy Volunteers Using Pregabalin And Ibuprofen As Positive Controls

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs PF 6273340 (Primary) ; Ibuprofen; Pregabalin
  • Indications Pain
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 27 Nov 2017 Primary endpoint (Electrical pain tolerance threshold (400mg and 50 mg vs placebo)) has not been met as per the results published in the British Journal of Clinical Pharmacology
    • 27 Nov 2017 Primary endpoint (Pressure pain tolerance threshold (400mg and 50 mg vs placebo)) has not been met as per the results published in the British Journal of Clinical Pharmacology
    • 27 Nov 2017 Primary endpoint (Ultra-violet light sensitized pain detection threshold (50mg vs placebo)) has not been met as per the results published in the British Journal of Clinical Pharmacology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top